OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
LOS ANGELES, CA, April 27, 2018 -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible Notes, through a Regulation D 506(b) offering to qualified buyers. The Notes would be convertible into Hoverink common stock and would have a two-year term. the Notes and the common stock issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes. Hoverink Biotechnologies, Inc., headquartered in Los Angeles, CA, is an independent preclinical biopharmaceutical company. The Company develops, manufactures, and commercializes pharmaceutical preparations and drug treatment for age-related diseases, cancer, mental illnesses, and gastrointestinal and oncological disorders. Hoverink Biotechnologies serves patients in the United States.
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, uncertainties related to the offering of the notes. Actual results could differ materially. for more information on Hoverink Biotechnologies, Inc. please visit the company's web site at http://www.hoverinkbiotech.yolasite.com/ or call the Hoverink Biotechnologies Corporate Communications Department at 866-443-4666 EXT 113
Contact: Cyrus Sajna Vice-President Hoverink Biotechnologies Inc, 1801 CENTURY PARK EAST, 24TH FLOOR LOS ANGELES, CA 90067 [email protected] 866-443-4666
